How We Invest

13F FILER • JAMES SILVERMAN

Opaleye Management

James Silverman — Opaleye Management Inc.

No writing by this manager has been read and indexed yet, so this page carries the filings only. Holdings come straight from the Form 13F-HR on EDGAR.

58

Positions

$1.1B

Reported Value

64.8%

In Top 10

—

Claims Indexed

Largest reported positions

OPALEYE MANAGEMENT INC. • CIK 0001595855 • 2026-06-30 • FILED 2026-08-14

WHAT CHANGED THIS QUARTER

In its Q2 2026 13F, filed Aug 14, 2026, Opaleye Management reported 58 positions worth $1.1B in US-listed stock. The largest stock position is Liquidia Corporation at 17.7% of the reported book, and the ten largest lines of any type make up 64.8% of it.

It opened 13 new positions, the largest stock positions being Immix Biopharma Inc ($24.2M), Monte Rosa Therapeutics Inc ($18.0M) and Replimune Group Inc ($15.3M), and exited 9, the largest stock exits being Perspective Therapeutics Inc ($19.5M last quarter), Assertio Holdings Inc ($5.1M last quarter) and Sutro Biopharma Inc ($4.7M last quarter).

Among positions it already held, the biggest increases by share count were Bridgebio Oncology Therapeut (+1214%), Lyell Immunopharma Inc (+335%) and 4D Molecular Therapeutics In (+198%), and the biggest cuts were Annexon Inc (−26%), Q32 Bio Inc (−26%) and Biodesix Inc (−24%).

Largest reported positions, quarter ended 2026-06-30
IssuerValueWeightShares QoQ
LIQUIDIA CORPORATION$195.1M17.7%-4%
ETON PHARMACEUTICALS INC$103.5M9.4%—
HARROW INC$101.9M9.2%-15%
DISC MEDICINE INC$62.5M5.7%+103%
UROGEN PHARMA LTD$53.0M4.8%+1%
APOGEE THERAPEUTICS INC$51.8M4.7%—
MEIRAGTX HLDGS PLC$48.0M4.3%+67%
SOL-GEL TECHNOLOGIES LTD$37.1M3.4%—
REZOLUTE INC$32.8M3.0%—
TG THERAPEUTICS INC$29.4M2.7%—
IMMIX BIOPHARMA INC$24.2M2.2%New
CRESCENT BIOPHARMA INC.$23.7M2.1%+1%
STOKE THERAPEUTICS INC$22.9M2.1%—
ALPHA COGNITION INC$20.9M1.9%+13%
EDGEWISE THERAPEUTICS INC$20.3M1.8%—
REVOLUTION MEDICINES INC$18.7M1.7%—
MONTE ROSA THERAPEUTICS INC$18.0M1.6%New
ALUMIS INC$15.5M1.4%—
CODEXIS INC$15.3M1.4%—
REPLIMUNE GROUP INC$15.3M1.4%New

20 of 58 positions. A 13F covers long US-listed positions at a quarter end only — no shorts, leverage, cash, ordinary bonds or private holdings — and is 45 days old on publication.

NEW POSITIONS

  • Immix Biopharma Inc$24.2M · 2.2%
  • Monte Rosa Therapeutics Inc$18.0M · 1.6%
  • Replimune Group Inc$15.3M · 1.4%
  • Verastem Inc$6.9M · 0.6%

EXITS

  • Perspective Therapeutics Inc$19.5M last quarter
  • Assertio Holdings Inc$5.1M last quarter
  • Sutro Biopharma Inc$4.7M last quarter
  • Tectonic Therapeutic Inc$3.8M last quarter
  • Rigel Pharmaceuticals Inc$1.9M last quarter

QUESTIONS PEOPLE ASK

What are Opaleye Management's largest holdings?

OPEN
As of Jun 30, 2026, the three largest stock positions are Liquidia Corporation (17.7%), Eton Pharmaceuticals Inc (9.4%) and Harrow Inc (9.2%), together 36.3% of the reported book.

How big is Opaleye Management's 13F portfolio?

OPEN
The Q2 2026 13F, filed Aug 14, 2026, reports 58 positions worth $1.1B. The ten largest make up 64.8% of it.

What did Opaleye Management buy and sell in Q2 2026?

OPEN
It opened 13 new positions, the largest stock positions being Immix Biopharma Inc ($24.2M), Monte Rosa Therapeutics Inc ($18.0M) and Replimune Group Inc ($15.3M), and exited 9, the largest stock exits being Perspective Therapeutics Inc ($19.5M last quarter), Assertio Holdings Inc ($5.1M last quarter) and Sutro Biopharma Inc ($4.7M last quarter). Among positions it already held, the biggest increases by share count were Bridgebio Oncology Therapeut (+1214%), Lyell Immunopharma Inc (+335%) and 4D Molecular Therapeutics In (+198%), and the biggest cuts were Annexon Inc (−26%), Q32 Bio Inc (−26%) and Biodesix Inc (−24%).

When is Opaleye Management's next 13F due?

OPEN
The Q3 2026 13F is due Nov 16, 2026. Forty-five days after the quarter ends is November 14, 2026 (Saturday), so the deadline moves to the next business day. James Silverman's filing usually lands close to the deadline.

Filers with overlapping books